New Hampshire Expands ‘Right to Try,’ Boosting Experimental Treatment Access - Governing
New Hampshire has expanded the 'Right to Try' law, allowing patients with terminal illnesses to access experimental treatments without FDA approval.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 2, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Patients with terminal illnesses and pharmaceutical manufacturers offering experimental treatments. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate effect; no specific deadline mentioned.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Expansion of the 'Right to Try' law increases access to experimental treatments for terminally ill patients.
Who it affects
Patients with terminal illnesses and pharmaceutical manufacturers offering experimental treatments.
What you must do
Pharmaceutical manufacturers should ensure compliance with the expanded provisions of the 'Right to Try' law when offering experimental treatments.
Deadline
Immediate effect; no specific deadline mentioned.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Colorado wins FDA approval for Canadian drug importation plan after years of effort - bizjournals.com
- Rescheduling Cannabis Under the Controlled Substances Act - theregreview.org
- U.S. Supreme Court Weighs Inducement Liability Beyond FDA Carve-Out Labels - spencerfane.com
- The FDA Is Cracking Down on an Indian Drugmaker Investigated by ProPublica Last Year - ProPublica
- Nevada’s Proposed New Regulations: What Pharmacies Need to Know - bipc.com